Items where authors include "Bayliss, R."

Article

Burgess, S.G., Paul, N.R., Richards, M.W. et al. (6 more authors) (2024) A nanobody inhibitor of Fascin-1 actin-bundling activity and filopodia formation. Open Biology, 14 (3). 230376. ISSN 2046-2441

Kim, M., Ju, H., Song, J. et al. (3 more authors) (2024) HER3 overexpression: a predictive marker for poor prognosis in advanced ALK-positive non-small cell lung cancer treated with ALK inhibitors. Translational Lung Cancer Research Journal, 13 (2). pp. 321-333. ISSN 2218-6751

Dawber, R.S., Gimenez, D., Batchelor, M. et al. (4 more authors) (2024) Inhibition of Aurora‐A/N‐Myc protein–protein interaction using peptidomimetics: Understanding the role of peptide cyclization. ChemBioChem, 25 (2). e202300649. ISSN 1439-4227

Bayliss, R. orcid.org/0000-0003-0604-2773, Sarnowska, E., Yeoh, S. et al. (1 more author) (2023) ALKing the flames of lung cancer immunosensitivity. Molecular Oncology, 17 (11). pp. 2218-2220. ISSN 1574-7891

Martin, H.L., Turner, A.L., Higgins, J. et al. (14 more authors) (2023) Affimer-mediated locking of p21-activated kinase 5 in an intermediate activation state results in kinase inhibition. Cell Reports, 42 (10). 113184. ISSN 2211-1247

O'Regan, L., Barone, G., Adib, R. et al. (10 more authors) (2020) EML4-ALK V3 oncogenic fusion proteins promote microtubule stabilization and accelerated migration through NEK9 and NEK7. Journal of Cell Science, 133 (9). jcs.241505. ISSN 0021-9533